Sanofi: Invest Securities still a buyer.
(CercleFinance.com) - Invest Securities has confirmed its buy rating on the Sanofi stock, along with a target price of 91 euros, after the group's acquisition of Protein Sciences and the presentation of additional results of fitusiran in patients suffering from hemophilia a and b.
"This phase ii confirms both the product's risk profile and its clinical activity (48% of the population did not show bleeding during the observation period)," the analyst said.
With alnylam, the broker's analysts also sees this partnership as "one of the examples of development that does not seem to be integrated into expectations and which could lead to a revaluation" of the French pharmaceutical giant.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"This phase ii confirms both the product's risk profile and its clinical activity (48% of the population did not show bleeding during the observation period)," the analyst said.
With alnylam, the broker's analysts also sees this partnership as "one of the examples of development that does not seem to be integrated into expectations and which could lead to a revaluation" of the French pharmaceutical giant.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.